Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

4608 - Trends of care of non-metastatic pancreas cancer patients in Ireland.

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Tumour Site

Pancreatic Cancer

Presenters

Rozana Abdul Rahman

Citation

Annals of Oncology (2018) 29 (suppl_8): viii205-viii270. 10.1093/annonc/mdy282

Authors

R. Abdul Rahman1, G. McVey2, M. Moriarty2, D. Maguire3, E. Hoti3, P. Ridgway3, K. Conlon3, J. Geoghegan3, R. McDermott1

Author affiliations

  • 1 Medical Oncology, St. Vincent's University Hospital, 4 - Dublin/IE
  • 2 Radiaiton Oncology, St. Luke's Hospital, Rathgar/IE
  • 3 Hepatobiliary Surgery, St Vincents University Hospital, Dublin/IE
More

Resources

Abstract 4608

Background

Surgery offers the only chance of cure in non-metastatic pancreatic cancer. However, chemo- and radio-therapy also play important roles in pancreatic cancer care. How each of these different modalities of treatment impact on pancreatic cancer outcome is unclear. The National Cancer Registry (NCRI) is a publicly appointed body, established to collect and classify information on all cancer cases which occur in Ireland. We analysed these data with the objective to examine the trend of care of stage 1 to 3 pancreas cancer in Ireland.

Methods

Pancreatic cancer data have been collected by NCRI since 1994. Only those with stage 1 – 3 adenocarcinoma of the pancreas (PDAC) were included in the final analyses. Descriptive statistics, Pearson chi-square test and survival analysis using Kaplan Meier curve with log-rank test and cox regression was performed.

Results

Between Jan 1994 and Dec 2013, of the 8230 patients with pancreatic cancer identified from the NCRI database, 4298 pts had histologically proven adenocarcinoma. Among these, 1177/27% of patients (pts) had stage 1 – 3 disease. 52% were male and 74% of pts were over 60 years of age. Stage 1, 2 and 3 disease comprised 25%, 32% and 42% of pts respectively. Overall 48 % of pts had surgery, 44% had chemotherapy and 21% had radiotherapy. 364, 31% pts did not have any therapy at all. Compared to those who did not have any treatment, there was an incremental benefit in overall survival (OS) with the more number of different modalities of treatment involved (Table). OS was 3 mos with no treatment, 8 mos with either chemo or radiation (HR 0.57), 11 mos with chemo and radiation (HR 0.46), 18 mos with surgery only (HR 0.27) and 20 mos with surgery with chemo and/or radiation therapy (HR 0.24).Table: 744P

NOSHR
No treatment364, 31%3 months
Multimodality therapies including surgery287, 25%20 months0.24 (95% CI: 0.20 – 0.28)
Surgery only245, 21%18 months0.27 (95% CI: 0.22 – 0.32)
Multimodality therapy (no surgery)95, 8%11 months0.46 (95% CI: 0.36 – 0.58)
Single modality therapy (no surgery)179, 16%8 months0.57 (95% CI: 0.48 – 0.69)

Conclusions

Multimodality therapy with surgery improves OS in non-metastatic pancreatic cancer with incremental benefit seen from even single modality therapy.

Clinical trial identification

Legal entity responsible for the study

Rozana Abdul Rahman, Ray McDermott.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.